Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supplement Claims For Autism Treatment Could Ring A Bell At FTC

This article was originally published in The Tan Sheet

Executive Summary

The firm that challenged Pursuit of Research’s claims and prompted a NAD review, NourishLife LLC, already incurred FTC enforcement about unsubstantiated claims that products treat childhood speech disorders.

You may also be interested in...



Prevagen Study Data Withstand False Ad Complaint By FTC, New York AG

A federal judge dismissed a complaint filed by FTC and New York AG Schneiderman against Quincy Biosciences about claims for Prevagen cognitive supplement. The complaint did not show the company violated the FTC Act because it pointed only to possible errors in a supporting study.

New York AG And FTC Target Prevagen Memory Claims

FTC and New York Attorney General file a lawsuit dietary alleging supplement marketer Quincy Bioscience preyed on elderly consumers with a multi-channel ad campaign claims its supplement Prevagen boosted memory.

NAD Could Jog Cognitive Benefit Supplement Firm's Memory With FTC Call

NAD refers UltraMax Health's supplement claim to the FTC after it fails to provide substantiation. CRN emphasizes claims alone are not the problem, but the firm's failure to provide substantiation.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS107728

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel